Idec begins Phase II in rheumatoid arthritis

IDPH started a double-blind, placebo-controlled Phase II trial of its primatized non-depleting anti-CD4 monoclonal antibody, clenoliximab (IDEC-151), in 130 patients with moderate to severe rheumatoid...